1 citations
,
January 2025 in “Annals of Dermatology” Baricitinib is effective and safe for treating alopecia areata in Korea.
1 citations
,
August 2024 in “Journal of Pharmacy & Pharmaceutical Sciences” The DPCP/HPβCD complex improves solubility and anti-inflammatory effects for alopecia areata treatment.
1 citations
,
July 2024 in “International Journal of Molecular Sciences” Effective delivery systems are crucial for siRNA hair loss treatments to work better.
1 citations
,
August 2023 in “Advanced Drug Delivery Reviews” Microneedles are promising for long-acting drug delivery and can improve patient compliance, but more data is needed to confirm their effectiveness.
1 citations
,
January 2021 in “Skin appendage disorders” Alopecia areata in children is usually mild and effectively treated with strong topical steroids.
1 citations
,
August 2005 in “Springer eBooks” Alopecia areata is an autoimmune disease with genetic links, treatable with certain medications, and can affect mental health.
March 2026 in “Journal of Nanotheranostics” Nanotechnology improves CRISPR-Cas9 delivery for cancer treatment, but challenges remain.
February 2026 in “International Journal of Molecular Sciences” Combining hyperthermia with natural compounds and conventional treatments improves cancer therapy effectiveness and reduces side effects.
February 2026 in “Stem Cell Research & Therapy” Stem cell therapies show promise for hair regrowth in alopecia areata but need more research for safety and effectiveness.
December 2025 in “Sensors” Microneedles in wearables can deliver drugs over time but face challenges in manufacturing and safety.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
October 2025 in “International Journal of Dermatology” Baricitinib is a safe and effective treatment for alopecia areata, with better results in patients with lower initial severity, shorter disease duration, and longer treatment.
October 2025 in “Dermatologica Sinica” A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.
October 2025 in “Pharmaceutics” Microneedles improve drug delivery for skin diseases, enhancing treatment effectiveness and patient compliance.
September 2025 in “Frontiers in Cell and Developmental Biology” TCM-derived nanovesicles show promise for wound healing and skin regeneration but need more research.
July 2025 in “Journal of Cosmetic Dermatology” Triamcinolone is more effective than methotrexate for treating localized alopecia areata.
July 2025 in “American Journal of Clinical Dermatology” Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.
July 2025 in “Journal of Integrated Health Sciences” Ayurvedic treatment effectively improved patchy hair loss using simple, cost-effective methods.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
March 2025 in “Journal of Education Health and Sport” Alopecia areata causes hair loss due to immune issues, and while new treatments show promise, no universally effective solution exists yet.
February 2025 in “Indian Dermatology Online Journal” Calcipotriol is the safest and most effective for hair regrowth in localized alopecia areata.
February 2025 in “Expert Opinion on Drug Metabolism & Toxicology” Future alopecia treatments will improve with targeted therapies and personalized approaches.
Alopecia Areata causes hair loss and needs treatments that address both physical and emotional health.
January 2025 in “AAPS PharmSciTech” Transethosomes improve drug delivery through the skin and show promise for treating various conditions.
December 2024 in “Antioxidants” Luteolin can reduce hair graying in mice, with external treatment being more effective.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
November 2024 in “Nanomaterials” The nanocrystalline suspension effectively delivers dutasteride over time with minimal inflammation.
September 2024 in “Pigment International” Vitiligo is now seen as a systemic disease with promising new treatments and may offer protection against some diseases.
August 2024 in “International Journal of Molecular Sciences” Androgenetic alopecia involves immune cell disruptions, especially increased CD4+ T cells around hair follicles.
August 2024 in “EMJ Dermatology” Non-scarring alopecia in females affects emotional well-being and requires accurate diagnosis and personalized treatment.